CD30-Positive Neoplastic Cells Present: Clinical Trials

2 trials for CD30-Positive Neoplastic Cells Present, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 withdrawn. 2 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 22Active not recruiting 1, Withdrawn 1
Phase 11Withdrawn 1

Follow CD30-Positive Neoplastic Cells Present: new trials by email Literature Review of CD30-Positive Neoplastic Cells Present trials Research Report on CD30-Positive Neoplastic Cells Present

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
Brentuximab Vedotin, Ceritinib, Laboratory Biomarker Analysis - Anaplastic Large Cell Lymphoma, ALK-Positive, CD30-Positive Neoplastic Cells Present
Phase 1 / Phase 2WithdrawnUniversity of Washington2018-01-032019-10-10
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
Brentuximab Vedotin, Laboratory Biomarker Analysis - CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma
Phase 2Active not recruitingM.D. Anderson Cancer Center252017-04-052026-08-25

Narrower conditions

Lymphoma, Large-Cell, Anaplastic (1)  ·  Mesothelioma, Malignant (1)

Broader conditions

Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Adenoma (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Lung Diseases (1)  ·  Lung Neoplasms (1)  ·  Lymphatic Diseases (1)  ·  Lymphoma (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Lymphoma, T-Cell (1)  ·  Lymphoproliferative Disorders (1)  ·  Mesothelioma (1)  ·  Neoplasms by Site (1)

Interventions

Brentuximab Vedotin (2)  ·  ceritinib (1)

Sponsors

M.D. Anderson Cancer Center (1)  ·  University of Washington (1)

Countries

United States (2)

Top investigators

Andrei Shustov (1)  ·  Anne S Tsao (1)

NIH funding

P30CA015704 (1)